Alnylam Cardiovascular Deal History & Licensing Activity
Alnylam Cardiovascular is a large biotech headquartered in US. Over the past three years, Alnylam Cardiovascular has been involved in 2 licensing and acquisition transactions, with a primary focus on Oligonucleotides (4 deals).
Deals (12mo)
1
Active Trials
15
Top Modality
Oligonucleotides
Focus Area
Other
Alnylam Cardiovascular Recent Deal Activity
Licensing, acquisition, and partnership transactions involving Alnylam Cardiovascular in the past 12 months.
| Asset | Partner | Modality | Phase | Type | Date |
|---|---|---|---|---|---|
| AI-enabled drug design collaboration | Alnylam | Oligonucleotides | Discovery | collaboration | Jun 7, 2026 |
| RNAi pipeline | Blackstone Life Sciences | Oligonucleotides | Unknown | collaboration | May 18, 2026 |
Alnylam Cardiovascular Pipeline Focus
Therapeutic areas and modalities where Alnylam Cardiovascular is most active based on deal history and clinical trial data.
Therapeutic Areas
Modalities
Alnylam Cardiovascular Strategic Signals
Key indicators of Alnylam Cardiovascular's licensing and acquisition strategy, including patent expirations, pipeline gaps, and strategic priorities.
Patent Cliffs
- Undisclosed—
Strategic Profile
Acquisition Appetite
Strategic Priorities
See How Your Asset Matches Alnylam Cardiovascular's Portfolio
Use Solidus to benchmark upfront payments, milestones, and royalties for Other assets — powered by data from 3,500+ real biopharma transactions.
Related Intelligence
Cardiovascular Deal Benchmarks
Market sizing, deal terms, and competitive landscape for cardiovascular
Oligonucleotides Benchmarks
Upfront, milestone, and royalty benchmarks for oligonucleotides deals
Deal Pulse
Track the latest biopharma licensing and acquisition deals across all therapeutic areas
All Company Profiles
Browse 850+ biotech and pharma company profiles with deal history and pipeline data
2026 Deal Benchmarks Report
Industry-wide analysis of deal terms, trends, and market dynamics
About Alnylam Cardiovascular Licensing & Deal Activity
Alnylam Cardiovascular is a large biotech company based in US that has been actively engaged in licensing transactions across the biopharma landscape. With 2 deals over the past three years, Alnylam Cardiovascular ranks among the actively acquisitive companies tracked by Ambrosia Ventures.
Key therapeutic areas of focus for Alnylam Cardiovascular include Other (2 deals and trials), and Cardiovascular (2 deals and trials). In terms of modality, Alnylam Cardiovascular has shown particular interest in oligonucleotides.
Ambrosia Ventures tracks deal terms, pipeline data, patent expirations, and competitive positioning for Alnylam Cardiovascular and 850+ other biopharma companies. Use our Solidus to benchmark your asset against Alnylam Cardiovascular's historical deal terms, or explore all company profiles to find the best partner match for your pipeline.